Defining the Pathway to Insulin-like Growth Factor System Targeting in Cancer

Overview

Journal Biochem Pharmacol

Specialties Biochemistry
Pharmacology

Date 2010 Jul 6

PMID 20599789

Citations 54

Authors

Steven A Rosenzweig

Hanudatta S Atreya

Affiliations

Soon will be listed here.

Abstract

The insulin-like growth factors (IGFs; IGF-1 and IGF-2) play central roles in cell growth, differentiation, survival, transformation and metastasis. The biologic effects of the IGFs are mediated by the IGF-1 receptor (IGF-1R), a receptor tyrosine kinase with homology to the insulin receptor (IR). Dysregulation of the IGF system is well recognized as a key contributor to the progression of multiple cancers, with IGF-1R activation increasing the tumorigenic potential of breast, prostate, lung, colon and head and neck squamous cell carcinoma (HNSCC). Despite this relationship, targeting the IGF-1R has only recently undergone development as a molecular cancer therapeutic. As it has taken hold, we are witnessing a robust increase and interest in targeting the inhibition of IGF-1R signaling. This is accentuated by the list of over 30 drugs, including monoclonal antibodies (mAbs) and tyrosine kinase inhibitors (TKIs) that are under evaluation as single agents or in combination therapies. The IGF-binding proteins (IGFBPs) represent the third component of the IGF system consisting of a class of six soluble secretory proteins. They represent a unique class of naturally occurring IGF-antagonists that bind to and sequester IGF-1 and IGF-2, inhibiting their access to the IGF-1R. Due to their dual targeting of the IGFs without affecting insulin action, the IGFBPs are an untapped "third" class of IGF-1R inhibitors. In this commentary, we highlight some of the significant aspects of and prospects for targeting the IGF-1R and describe what the future may hold.

Citing Articles

Enhanced stability of an intrinsically disordered protein against proteolytic cleavage through interactions with silver nanoparticles.

Malik S, Mondal S, Atreya H RSC Adv. 2022; 9(49):28746-28753.

PMID: 35529627 PMC: 9071183. DOI: 10.1039/c9ra05514b.

IGF-dependent dynamic modulation of a protease cleavage site in the intrinsically disordered linker domain of human IGFBP2.

Jaipuria G, Shet D, Malik S, Swain M, Atreya H, Galea C Proteins. 2022; 90(9):1732-1743.

PMID: 35443068 PMC: 9357107. DOI: 10.1002/prot.26350.

Therapeutic Potential of Thymoquinone in Triple-Negative Breast Cancer Prevention and Progression through the Modulation of the Tumor Microenvironment.

Adinew G, Taka E, Mochona B, Badisa R, Mazzio E, Elhag R Nutrients. 2022; 14(1).

PMID: 35010954 PMC: 8746460. DOI: 10.3390/nu14010079.

Clinicopathologic significance of TROP2 and phospho-TROP2 in gastric cancer.

Kushiyama S, Yashiro M, Yamamoto Y, Sera T, Sugimoto A, Nishimura S Mol Clin Oncol. 2021; 14(5):105.

PMID: 33815794 PMC: 8010512. DOI: 10.3892/mco.2021.2267.

IGF-1/IGF-1R/FAK/YAP Transduction Signaling Prompts Growth Effects in Triple-Negative Breast Cancer (TNBC) Cells.

Rigiracciolo D, Nohata N, Lappano R, Cirillo F, Talia M, Scordamaglia D Cells. 2020; 9(4).

PMID: 32325700 PMC: 7225986. DOI: 10.3390/cells9041010.

References

Yee D . Targeting insulin-like growth factor pathways. Br J Cancer. 2006; 94(4):465-8. PMC: 2361182. DOI: 10.1038/sj.bjc.6602963. View

Rozengurt E, Sinnett-Smith J, Kisfalvi K . Crosstalk between insulin/insulin-like growth factor-1 receptors and G protein-coupled receptor signaling systems: a novel target for the antidiabetic drug metformin in pancreatic cancer. Clin Cancer Res. 2010; 16(9):2505-11. PMC: 2862089. DOI: 10.1158/1078-0432.CCR-09-2229. View

Shimizu M, Deguchi A, Hara Y, Moriwaki H, Weinstein I . EGCG inhibits activation of the insulin-like growth factor-1 receptor in human colon cancer cells. Biochem Biophys Res Commun. 2005; 334(3):947-53. DOI: 10.1016/j.bbrc.2005.06.182. View

Lucas Jr J, Salimath B, Slomiany M, Rosenzweig S . Regulation of invasive behavior by vascular endothelial growth factor is HEF1-dependent. Oncogene. 2010; 29(31):4449-59. PMC: 2921319. DOI: 10.1038/onc.2010.185. View

DeChiara T, Robertson E, Efstratiadis A . Parental imprinting of the mouse insulin-like growth factor II gene. Cell. 1991; 64(4):849-59. DOI: 10.1016/0092-8674(91)90513-x. View

Ratain M, Glassman R . Biomarkers in phase I oncology trials: signal, noise, or expensive distraction?. Clin Cancer Res. 2007; 13(22 Pt 1):6545-8. DOI: 10.1158/1078-0432.CCR-07-2133. View

Knowlden J, Jones H, Barrow D, Gee J, Nicholson R, Hutcheson I . Insulin receptor substrate-1 involvement in epidermal growth factor receptor and insulin-like growth factor receptor signalling: implication for Gefitinib ('Iressa') response and resistance. Breast Cancer Res Treat. 2007; 111(1):79-91. DOI: 10.1007/s10549-007-9763-9. View

Van den Berg C, Cox G, Stroh C, Hilsenbeck S, Weng C, McDermott M . Polyethylene glycol conjugated insulin-like growth factor binding protein-1 (IGFBP-1) inhibits growth of breast cancer in athymic mice. Eur J Cancer. 1997; 33(7):1108-13. DOI: 10.1016/s0959-8049(97)00071-3. View

Song R, Chen Y, Zhang Z, Bao Y, Yue W, Wang J . Estrogen utilization of IGF-1-R and EGF-R to signal in breast cancer cells. J Steroid Biochem Mol Biol. 2009; 118(4-5):219-30. PMC: 2826506. DOI: 10.1016/j.jsbmb.2009.09.018. View

10.

Zhang L, Zhou W, Velculescu V, Kern S, Hruban R, Hamilton S . Gene expression profiles in normal and cancer cells. Science. 1997; 276(5316):1268-72. DOI: 10.1126/science.276.5316.1268. View

11.

Swain M, Slomiany M, Rosenzweig S, Atreya H . High-yield bacterial expression and structural characterization of recombinant human insulin-like growth factor binding protein-2. Arch Biochem Biophys. 2010; 501(2):195-200. PMC: 2934857. DOI: 10.1016/j.abb.2010.06.006. View

12.

Hoeflich A, Reisinger R, Lahm H, Kiess W, Blum W, Kolb H . Insulin-like growth factor-binding protein 2 in tumorigenesis: protector or promoter?. Cancer Res. 2001; 61(24):8601-10. View

13.

Chang Q, Li Y, White M, Fletcher J, Xiao S . Constitutive activation of insulin receptor substrate 1 is a frequent event in human tumors: therapeutic implications. Cancer Res. 2002; 62(21):6035-8. View

14.

Clemmons D . Use of mutagenesis to probe IGF-binding protein structure/function relationships. Endocr Rev. 2001; 22(6):800-17. DOI: 10.1210/edrv.22.6.0449. View

15.

Schwartz G . Vitamin D and intervention trials in prostate cancer: from theory to therapy. Ann Epidemiol. 2008; 19(2):96-102. DOI: 10.1016/j.annepidem.2008.03.007. View

16.

Hartog H, Wesseling J, Boezen H, van der Graaf W . The insulin-like growth factor 1 receptor in cancer: old focus, new future. Eur J Cancer. 2007; 43(13):1895-904. DOI: 10.1016/j.ejca.2007.05.021. View

17.

Peng L, J Malloy P, Feldman D . Identification of a functional vitamin D response element in the human insulin-like growth factor binding protein-3 promoter. Mol Endocrinol. 2004; 18(5):1109-19. DOI: 10.1210/me.2003-0344. View

18.

Chandrashekaran I, Yao S, Wang C, Bansal P, Alewood P, Forbes B . The N-terminal subdomain of insulin-like growth factor (IGF) binding protein 6. Structure and interaction with IGFs. Biochemistry. 2007; 46(11):3065-74. DOI: 10.1021/bi0619876. View

19.

Goda N, Tenno T, Inomata K, Shirakawa M, Tanaka T, Hiroaki H . Intracellular protein delivery activity of peptides derived from insulin-like growth factor binding proteins 3 and 5. Exp Cell Res. 2008; 314(13):2352-61. DOI: 10.1016/j.yexcr.2008.05.008. View

20.

Wactawski-Wende J, Kotchen J, Anderson G, Assaf A, Brunner R, OSullivan M . Calcium plus vitamin D supplementation and the risk of colorectal cancer. N Engl J Med. 2006; 354(7):684-96. DOI: 10.1056/NEJMoa055222. View